Dexcel Pharma USA — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Dexcel Pharma USA is the U.S. subsidiary of Israel's largest private pharmaceutical company, Dexcel Pharma, established following the 2022 acquisition of Edenbridge Pharmaceuticals and a 2024 rebranding. The company commercializes a portfolio of generic, branded, and specialty products, with a strategic focus on complex conditions like multiple myeloma and Gaucher disease. It leverages its parent company's global R&D and manufacturing scale to provide affordable, high-quality medications, positioning itself as a trusted partner in the U.S. generic and specialty pharmaceutical market.

OncologyCardiologyNeurologyGastroenterologyUrologyRare Diseases

Technology Platform

Not a distinct technology platform company. Leverages parent company's pharmaceutical development and manufacturing expertise for complex generics, branded, and specialty product formulation, regulatory strategy, and commercialization.

Opportunities

Growth in the specialty and rare disease market, particularly in oncology and metabolic disorders, offers higher margins and defensible positions.

Leveraging the global R&D and manufacturing scale of its parent company, Dexcel Pharma, can provide a competitive edge in cost and quality for its generic portfolio and facilitate the introduction of new complex products to the U.S.

market.

Risk Factors

The company faces intense pricing pressure and competition in the generic drug market, which could erode profitability.

Regulatory risks related to manufacturing compliance and product approvals are ever-present.

Future growth is dependent on successful business development to in-license or acquire new products, as the existing portfolio is subject to generic competition and patent cliffs.

Competitive Landscape

Dexcel Pharma USA competes with large generic pharmaceutical companies (e.g., Teva, Sandoz, Mylan) in the broad generics market and with other specialty pharma and biotech companies in niche areas like multiple myeloma and Gaucher disease. Its differentiation lies in its focus on specific complex therapies, private company agility, and the backing of a large international pharmaceutical manufacturer.

More companies in Small Molecule Drugs →More companies in United States →